Search for a trial

MRI study to prepare for adaptive MRI-guided radiation of prostate carcinoma.

The aim of the study is to investigate the effect of magnetic resonance (MR) based online adaptive radiotherapy (RT) for treatment of low to intermediate risk localized prostate carcinoma (PCa) on the radiotherapy dose on the prostate and organs at…

Quantitative mpMRI to predict metastatic potential of prostate cancer

The primary objective of this study is to assess the potential of quantitative MRI parameters to predict nodal disease stage of prostate cancer by correlating quantitative MRI measurements of the local prostate to the presence of metastases as seen…

Finger Prick blood collection validation studies

Determine whether the finger prick blood collection procedure can reliably replace venepuncture blood collection for the following tests: PSA, Covid-19 serology, HbA1c and a series of standard and routine chemistry tests.

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic
Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

This study has been transitioned to CTIS with ID 2023-506987-15-00 check the CTIS register for the current data. 1) Objective: To evaluate the safety and tolerability of the pembrolizumab combination therapy.2) Objective: To estimate PSA response…

Tolerability of concurrent EBRT + Lu-PSMA for node-positive prostate cancer (PROQURE-1)

This study has been transitioned to CTIS with ID 2024-514168-15-00 check the CTIS register for the current data. Primary: To determine the maximum tolerated dose (MTD) of 1 or 2 cycli Lu-PSMA when given concurrent with EBRT+ADT. Secondary: To…

Phase I dose escalation study to evaluate tolerability and safety of 225Ac-PSMA in patients with metastatic prostate cancer

This study has been transitioned to CTIS with ID 2024-513729-22-01 check the CTIS register for the current data. 1.1 Primary study objectives To investigate the safety, tolerability and biochemical effects of 225Ac-PSMA injected in patients with…

Improving the algorithm and preliminary assessment of the performance of 3D multiparametric ultrasound for the detection, grading and localization of prostate cancer

The primary objective is to collect high-quality 3D mpUS and histology data, to train and improve the classifier algorithm with the goal of achieving an accurate ultrasound imaging tool for the detection of clinically significant prostate cancer.…

A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell engager, alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory metastatic castration resistant prostate cancer

This study has been transitioned to CTIS with ID 2024-515821-27-00 check the CTIS register for the current data. Primary objectivesPart 1 Dose Escalation for LAVA-1207 alone, LAVA-1207 plus LDSC IL-2, and LAVA-1207 plus pembrolizumab• To investigate…

MultiSPectral fLuorescence Imaging as a Tool to separate healthy and disease related lymphatic anatomies during lymph node dissections in prostate cancer.

We aim to evaluate the technical feasibility of imaging two different lymphatic drainage profiles, namely that of healthy tissue (i.e. the lower limbs/abdominal wall) and that of the primary tumor (i.e. prostate). To realize the differentiation,…

An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies

This study has been transitioned to CTIS with ID 2022-502084-38-00 check the CTIS register for the current data. Primary- Continuation of treatment- SafetySecondairy- Documentation of tolerability

A Phase 1 Study of JNJ-78278343, a T Cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

This study has been transitioned to CTIS with ID 2023-506585-31-00 check the CTIS register for the current data. The study contains 2 parts: Part 1 is the dose escalation part. Part 2 is the dose expansion part.The primary objective of part 1 is to…

TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

This study has been transitioned to CTIS with ID 2024-510809-28-00 check the CTIS register for the current data. Primary objectiveTo demonstrate that talazoparib in combination with enzalutamide is superior to placebo in combination with…

HYPo-fractionated Radiotherapy of Lymph Node Metastases guided by NanO-MRI in Prostate Cancer Patients: A Pilot Study (HYPNO-study)

To evaluate the feasibility and efficacy of MR-guided stereotactic body radiotherapy (SBRT) to nano-MRI detected regional lymph node metastases in patients with biochemical recurrent prostate cancer after radical prostatectomy.

Prospective Randomized Controlled Trial To Evaluate The Prognostic Role of Lymph Node Dissection In Men With Prostate Cancer Treated With Radical Prostatectomy (PREDICT-Study)

To compare the oncologic outcomes of PCa patients with an estimated risk of lymph node invasion of 5-20% according to the Briganti nomogram without metastases on PSMA PET/CT undergoing a radical prostatectomy (RP) with or without an ePLND.

DISCOVER study: Detecting Increased Susceptibility for Cancer in relatives by Offering genetic Variant Evaluation as Regular health care: prostate cancer

Mainstreaming of germline genetic tests in regular healthcare is feasible for healthcare professionals and acceptable for both patients and healthcare professionals